Saatja: PIRGARI, Dorina <
[email protected]>
Saadetud: 22.11.2020 22:52
Adressaat: Elen Ohov <
[email protected]>
Koopia: Triin Uusberg <
[email protected]>; SM Info <
[email protected]>;
<
[email protected]>; <
[email protected]>; <
[email protected]>;
<
[email protected]>; KÖHLER, Kristina <
[email protected]>;
POLISHCHUK, Olexandr <
[email protected]>; LINDHARDT, Lisbeth Sjaelborg
<
[email protected]>; MCLAREN, Joanne Michaela <
[email protected]>
Teema: EST_Request for official nomination of a National Focal Point to
the WHO Global Focal Point Network for substandard and falsified (SF)
medical products
Please see the attached correspondence sent from the World Health
Organization, Regional Office for Europe. One or more attachments may be
included.Veuillez vous r¨¦f¨¦rer ¨¤ la correspondance ci-jointe du Bureau
r¨¦gional de l'Europe de l'Organisation mondiale de la sant¨¦. Une ou
plusieurs annexes peuvent ¨ºtre jointes.Mit der Bitte um Kenntnisnahme
der beiliegenden Korrespondenz (eine oder mehrere Anlagen),
Weltgesundheitsorganisation, Regionalb¨¹ro f¨¹r Europa.
§³§Þ. §á§â§Ú§Ü§â§Ö§á§Ý§Ö§ß§ß§à§Ö §á§Ú§ã§î§Þ§à §à§ä
§¦§Ó§â§à§á§Ö§Û§ã§Ü§à§Ô§à §â§Ö§Ô§Ú§à§ß§Ñ§Ý§î§ß§à§Ô§à §Ò§ð§â§à
§£§ã§Ö§Þ§Ú§â§ß§à§Û §à§â§Ô§Ñ§ß§Ú§Ù§Ñ§è§Ú§Ú §Ù§Õ§â§Ñ§Ó§à§à§ç§â§Ñ§ß§Ö§ß§Ú§ñ
(§à§Õ§Ú§ß §Ú§Ý§Ú §ß§Ö§ã§Ü§à§Ý§î§Ü§à §á§â§Ú§Ü§â§Ö§á§Ý§Ö§ß§ß§í§ç
§æ§Ñ§Û§Ý§à§Ó).
Regards,
Dorina Pirgari DSP/HTP/WHO EURO
Tel. +45 45 33 71 07
Mob. +45 91 98 66 95
E-mail:
WORLD HEALTH ORGANIZATION
ORGANISATION MONDIALE DE LA SANTÉ
WELTGESUNDHEITSORGANISATION
ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ Date: 18 November 2020
REGIONAL OFFICE FOR EUROPE Ms Elen Ohov
BUREAU RÉGIONAL DE L’EUROPE
REGIONALBÜRO FÜR EUROPA
Adviser
ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО European Union Affairs and International Co-operation
Department
Head office:
Ministry of Social Affairs
UN City, Marmorvej 51,
DK-2100 Copenhagen Ø, Denmark Suur-Ameerika 1
Tel.: +45 45 33 70 00; Fax: +45 45 33 70 01 10122 Tallinn
Email:
[email protected] Estonia
Website: http://www.euro.who.int
Our reference: Your reference:
Notre référence: Votre référence:
Unser Zeichen: Ihr Zeichen:
См. наш номер: На Ваш номер:
Dear Ms Ohov,
Request for official nomination of a National Focal Point to the
WHO Global Focal Point Network for substandard and falsified (SF) medical products
As part of WHO’s fundamental role in protecting public health, the Sixty-fifth World Health Assembly
resolution WHA65.19 established a Member State mechanism to tackle substandard and falsified (SF) medical
products. The Member State mechanism identified the need within their workplan for the creation of a Global
Focal Point Network of national/regional regulatory authorities.
Additionally, in 2013, WHO developed the Global Surveillance and Monitoring System (GSMS), which is
designed to receive reports from national regulatory authorities (NRAs) concerning either suspected or
confirmed SF medical products. This significantly improves the quantity and quality of data on SF medical
products, provides technical support, and publishes medical products alerts. Currently,
experts from 123 Member States’ regulatory authorities are trained in the use of the GSMS.
At the fourth meeting of the Member State mechanism on SF medical products, held in Geneva, Switzerland in
November 2015, the Member States agreed to the terms of reference to “create a focal point network for the
exchange of information and consultation at large among Member States and establish an ongoing virtual
exchange forum”. The full terms of reference are attached.
As agreed by the Member State mechanism, and in order to establish the Global Focal Point Network, WHO is
now contacting the ministries of health in Member States, asking them to nominate or confirm a specific
member of the NRA’s technical staff to act as the National Focal Point, and in addition where possible, a
deputy, also from within the NRA. Therefore, where possible, two technical staff members should be
nominated (the National Focal Point and the deputy).
The National Focal Point(s) will be authorized to conduct searches for SF medical products that have been
reported to the GSMS. They will also be responsible for reporting SSFFC medical products to the GSMS and
will be the first point of contact for SF medical product-related matters between WHO and your NRA. Please
note that each NRA is responsible for informing WHO of any changes in personnel or contact details regarding
the nominated National Focal Point or their deputy. These contact details will be continuously updated and
annually confirmed by WHO headquarters.
You are requested to confirm the contact details (names and email addresses) of your nominated National Focal
Point and their deputy to the WHO Regional Office for Europe by email at
[email protected], copying
Dr Olexandr Polishchuk at
[email protected], by 30 November 2020 at the latest.
UN City, Marmorvej 51 Tel.: +45 45 33 70 00 Email:
[email protected]
DK-2100 Copenhagen Ø Fax: +45 45 33 70 01 Website: http://www.euro.who.int
Denmark
On receipt of your official nomination(s), the National Focal Point and their deputy will be sent all necessary
information.
Should you have any questions or require any further information, please do not hesitate to contact us.
Sincerely yours,
Dr Natasha Azzopardi Muscat
Director
Division of Country Health Policies and Systems
Encls:
Terms of reference for the National Focal Points
Copy for information to:
Ms Triin Uusberg, Head, European and International Coordination Department, Ministry of Social Affairs,
Suur-Ameerika 1, 10129 Tallinn, Estonia
H.E. Ms Katrin Saarsalu-Layachi, Ambassador Extraordinary and Plenipotentiary, Permanent Representative,
Permanent Mission of the Republic of Estonia to the United Nations Office and other international
organizations in Geneva, Chemin du Petit-Saconnex 28A, CH-1209 Genève, Switzerland
H.E. Mr William Mart Laanemäe, Ambassador Extraordinary and Plenipotentiary, Embassy of the Republic of
Estonia, Frederiksgade 19, 4th floor, 1265 Copenhagen K, Denmark
Ms Kristina Köhler, Liaison Officer, WHO Country Office, Estonia, Paldiski Road 81, 10617 Tallinn, Estonia
–2–
FOURTH MEETING OF THE MEMBER STATE MECHANISM ON
SUBSTANDARD/SPURIOUS/FALSELY-LABELLED A/MSM/4/2
FALSIFIED/COUNTERFEIT MEDICAL PRODUCTS 6 November 2015
Provisional agenda item 4B
Create a focal point network for the exchange of
information and consultation at large among
Member States and establish an ongoing
virtual exchange forum
Terms of reference for the Global Focal Point Network for
substandard/spurious/falsely-labelled/falsified/
counterfeit (SSFFC) medical products
Report by the Secretariat1
1. The establishment of a global network of focal points for the exchange of information and
consultation at large among Member States, and establish an ongoing virtual exchange forum was
agreed and prioritized by the Member State mechanism at its third meeting held in October 2014.2
2. Recognizing the global nature of the manufacture, distribution and sale of medical products, the
Member State mechanism has identified the need for a global network of focal points within WHO
Member States to improve the flow and exchange of information from a public health perspective in a
safe, secure and efficient environment. The creation of such a network has the potential to improve
reporting and alerting of SSFFC medical products, learn from the experience of other Member States
and provide access to a reliable source of information in a timely and efficient way.
3. This draft document is intended to provide a basis for discussion in setting the terms of
reference for a focal point network relating to SSFFC medical products. It recognizes that networks
exist in many regions and subregions and does not attempt to replace any of those networks but rather
endeavours to ensure global coordination, consistency and possible integration in approach. The WHO
global surveillance and monitoring system for SSFFC medical products has established focal points
within national regulatory authorities within over 90 Member States, and these terms of reference
would apply to those focal points.
1
The terms of reference below are based on the original draft prepared by Switzerland, United Kingdom of Great
Britain and Northern Ireland and the Secretariat. They take account of comments received from Member States.
2
See document A/MSM/3/3 Annex 3.
A/MSM/4/2
4. Whilst the Member State mechanism has chosen to use the term “focal points” this is
interchangeable with the term “single point of contact” currently used in some regions. It is important
that the focal point is integrated into existing national and regional alert structures in order to avoid
duplication and build synergies. Whilst the National focal point can be a specific group or department
within the national medicines regulatory authority, Member States are encouraged to nominate
specific personnel within that group or department as focal points, and that those nominated are
appropriate for the role, have access to the relevant information and have the support of their senior
management to share information in a timely way with the network.
5. The intention of creating this network is to ensure that enquiries and information concerning
SSFFC medical products are channelled through to the most appropriate office, and that office is
responsible for receiving, communicating and responding to SSFFC-related matters.
6. It is for Member States to identify and nominate the most appropriate office and person(s) to
receive, communicate and respond to enquiries relating to SSFFC medical products based on their
regulatory and administrative structures.
7. The terms of reference for a nominated national focal point for SSFFC medical products are as
follows:
(a) The national focal point should be situated within the national medicine regulatory
authority, and acts on behalf of that authority.
(b) To serve as the national focal point representative, Member States are encouraged to
nominate a specific member of staff, and where possible a deputy within the national medicines
regulatory authority, and their contact details including office address, telephone number and
email address provided to the WHO Member State mechanism secretariat. Generic email
addresses are acceptable, but the names of the nominated focal points should be notified to the
WHO Secretariat. It is the responsibility of national medicine regulatory authorities to inform
the WHO Secretariat of any changes in personnel or contact details. The designated focal point
is to act only on behalf of its national medicines regulatory authority and not in his/her personal
capacity.
(c) With the provision of the contact details to the WHO Secretariat the nominee agrees to
the disclosing of his/her contact details to the other National focal points within the network.
The WHO Secretariat will regularly circulate and update the list with contact details to all
nominated focal points. The list will be treated as strictly confidential by all nominees.
(d) If an existing national focal point or single point of contact within a national medicine
regulatory authority for SSFFC medical products has already been identified and/or trained they
should be considered for nomination to the network, so as to avoid duplication of effort.1
(e) The nominated focal point should be empowered to closely cooperate with the quality
control laboratories, national pharmacovigilance centres, national poisons centres and other
relevant government entities to ensure that suspected SSFFC medical products are identified
and responded to quickly and proportionately.
1
India is suggesting deletion of subparagraph 7(d) as this is not directly relevant to the terms of reference. The
identification and nomination of individuals as focal points should be left completely to national governments.
2
A/MSM/4/2
(f) The nominated focal point should establish effective and efficient working relationships
with the appropriate law enforcement agencies and other national institutions and the national
criminal justice system to ensure that suspected SSFFC medical products are identified and
responded to quickly and proportionately.1
(g) The nominated national focal point should be trained on the use of the WHO global
surveillance and monitoring system for the reporting of SSFFC medical products, and in
compliance with their own Member State laws and regulations concerning disclosure of
information pertinent to the WHO surveillance and monitoring system.
(h) The nominated focal point under the direction of the national medicine regulatory
authority should be empowered to receive and respond appropriately to all national, regional
and global medical product alerts.
(i) The nominated focal point should establish effective and efficient working relationships
with health-care providers to ensure that suspected SSFFC medical products are responded to
quickly and proportionately.2
(j) Where national systems exist for patient reporting of suspected SSFFC medical products,
close cooperation between the national focal point and such systems should be established to
ensure that suspected SSFFC medical products are responded to quickly and proportionately.3
(k) The nominated focal point should establish an effective and efficient working relationship
with those engaged in the licensed manufacture, distribution and supply of medical products to
ensure that suspected SSFFC medical products are identified and responded to quickly and
proportionately.3
(l) Nominated focal points should be trained in the use of an electronic platform to be
created and administered by WHO Secretariat to enable secure communication with their
counterparts from other Member States. All communications under the focal point network
should be routed through this online platform.
8. The WHO Secretariat will retain and maintain the list of nominated focal points and administer
the secure online platform.
1
India is suggesting deletion of subparagraph 7(f). Such coordination should be left to the national medicine
regulatory authority and not to the designated person. The focal point function should be limited to facilitating
communication between WHO and the national medicine regulatory authority regarding issuing an alert or follow-up action
after detection of SSFFC medical products. Also, it is impractical to expect this one focal point to have such wide authority.
2
India is suggesting deletion of subparagraph 7(i). As agreed under the prioritized list of activities for the Member
State mechanism, activity B refers to the establishment of a network of focal points for the exchange of information and
consultation at large among Member States. Item I of the terms of reference goes beyond this mandate and seems to be
prescriptive.
3
See footnote 1 above.
3
A/MSM/4/2
9. The Secretariat should ensure transparency in its activities with the focal point network and
such activities should be reported to the Member State mechanism through the Steering Committee.
WHO Secretariat shall ensure that training and other activities with the focal point network shall be
free from conflict of interest. In addition, the Secretariat shall not accept any financial contribution
from the pharmaceutical or medical devices or diagnostic industry or other non-State actors linked to
pharmaceutical or medical devices or diagnostic industry.1
= = =
1
Paragraph 9 inserted by India. However it should be noted that the conduct of the WHO Secretariat is governed by
existing rules and procedures.
4